Oramed Pharmaceuticals (FRA:OJU1) Long-Term Capital Lease Obligation : €0.25 Mil (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Oramed Pharmaceuticals Long-Term Capital Lease Obligation?

Oramed Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.25 Mil.

Oramed Pharmaceuticals's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€0.36 Mil) to Dec. 2023 (€0.31 Mil) and declined from Dec. 2023 (€0.31 Mil) to Mar. 2024 (€0.25 Mil).

Oramed Pharmaceuticals's annual Long-Term Capital Lease Obligation increased from Aug. 2021 (€0.34 Mil) to Dec. 2022 (€0.61 Mil) but then declined from Dec. 2022 (€0.61 Mil) to Dec. 2023 (€0.31 Mil).

Oramed Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Oramed Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Long-Term Capital Lease Obligation Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.03

0.34

0.61

0.31

Oramed Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.53	0.45	0.36	0.31	0.25

Oramed Pharmaceuticals (FRA:OJU1) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Oramed Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (FRA:OJU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (FRA:OJU1) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ORMP:USA

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.

Oramed Pharmaceuticals (FRA:OJU1) Headlines

No Headlines